MARKET

NYMX

NYMX

Nymox Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3827
+0.0027
+0.71%
After Hours: 0.3969 +0.0142 +3.71% 18:16 05/25 EDT
OPEN
0.4274
PREV CLOSE
0.3800
HIGH
0.4274
LOW
0.3701
VOLUME
592.60K
TURNOVER
0
52 WEEK HIGH
2.270
52 WEEK LOW
0.3502
MARKET CAP
34.55M
P/E (TTM)
-2.1179
1D
5D
1M
3M
1Y
5Y
58 Biggest Movers From Yesterday
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million.
Benzinga · 1d ago
HIVE, XIN and NEON among mid-day movers
Gainers: Lixiang Education Holding (LXEH) +62%. GeoVax Labs (GOVX) +50%. Sonder Holdings (SOND) +30%. O2Micro International (OIIM) +30%. Evolving Systems (OTC:EVOL) +28%. GoldMining (GLDG) +27%. Neonode (NEON) +24%. Mesa Royalty
Seekingalpha · 2d ago
Stocks That Hit 52-Week Lows On Monday
  On Monday, 149 companies reached new 52-week lows.
Benzinga · 2d ago
GeoVax, Entasis top healthcare gainers, while Nymox, Evoke Pharma lead losers' pack
Gainers: GeoVax Labs GOVX +39%. Entasis Therapeutics ETTX +21%. Allarity Therapeutics (ALLR) +14%. Tonix Pharmaceuticals (TNXP) +13%. TRxADE HEALTH (MEDS) +13%. Losers: Nymox Pharmaceutical NYMX -67%. Evoke Pharma EVOK -21%. NanoViricides (NNVC) -19%. Brig...
Seekingalpha · 2d ago
Why Nymox Pharma Shares Sinking to 52-Week Low?
Benzinga · 2d ago
NYMOX down 46% on Refuse to File letter from FDA for fexapotide for enlarged prostate
Shares of NYMOX Pharmaceutical (NASDAQ:NYMX) have plummeted 46% after the company received a Refuse to File letter from the U.S. FDA for its New Drug Application for fexapotide triflutate for benign prostate
Seekingalpha · 2d ago
BRIEF-Nymox Receives RTF Letter From FDA
reuters.com · 2d ago
Nymox Pharma Reports Received Refusal To File Letter From FDA Related To Co.'s New Drug Application For Fexapotide Triflutate
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at 2:48 pm EST, with regard to the Company's New Drug
Benzinga · 2d ago
More
No Data
Learn about the latest financial forecast of NYMX. Analyze the recent business situations of Nymox Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chairman/Chief Executive Officer/President/Director
Paul Averback
Chief Financial Officer
Erik Danielsen
General Counsel/Director
Randall Lanham
Independent Director
Richard Cutler
Independent Director
David Morse
Independent Director
James Robinson
No Data
No Data
About NYMX
Nymox Pharmaceutical Corporation is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. The Company’s Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert.

Webull offers kinds of Nymox Pharmaceutical Corp stock information, including NASDAQ:NYMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NYMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NYMX stock methods without spending real money on the virtual paper trading platform.